Verapamil Hydrochloride Injection, USP is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White and Lown-Ganong- Levine syndromes).
From the U.S. FDA-approved label for Verapamil. Full label: DailyMed.
Verapamil Hydrochloride Injection, USP is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White and Lown-Ganong- Levine syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration., Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White (W-P-W) and Lown-Ganong-Levine (L-G-L) syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%.
From the U.S. FDA-approved label for Verapamil. Full label: DailyMed.
(For Intravenous Use Only) VERAPAMIL HYDROCHLORIDE INJECTION SHOULD BE GIVEN AS A SLOW INTRAVENOUS INJECTION OVER AT LEAST A TWO-MINUTE PERIOD OF TIME UNDER CONTINUOUS ELECTROCARDIOGRAPHIC (ECG) AND BLOOD PRESSURE MONITORING. The recommended intravenous doses of verapamil hydrochloride injection are as follows: Adult: Initial dose − 5 to 10 mg (0.075 to 0.15 mg/kg body weight) given as an intravenous bolus over at least 2 minutes. Repeat dose - 10 mg (0.15 mg/kg body weight) 30 minutes after the first dose if the initial response is not adequate.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Verapamil hydrochloride injection is contraindicated in: 1. Severe hypotension or cardiogenic shock. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker). Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol).
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
VERAPAMIL HYDROCHLORIDE SHOULD BE GIVEN AS A SLOW INTRAVENOUS INJECTION OVER AT LEAST A TWO-MINUTE PERIOD OF TIME ( see Dosage And Administration ). Hypotension: Verapamil hydrochloride injection often produces a decrease in blood pressure below baseline levels that is usually transient and asymptomatic but may result in dizziness. Systolic pressure less than 90 mm Hg and/or diastolic pressure less than 60 mm Hg was seen in 5% to 10% of patients in controlled U.S. trials in supraventricular tachycardia and in about 10% of the patients with atrial flutter/fibrillation.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following reactions were reported with verapamil hydrochloride injection used in controlled U.S. clinical trials involving 324 patients: Cardiovascular: Symptomatic hypotension (1.5%); bradycardia (1.2%); severe tachycardia (1.0%). The worldwide experience in open clinical trials in more than 7,900 patients was similar. Central Nervous System Effects: Dizziness (1.2%); headache (1.2%).
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
16 products from 7 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Calaptin 120 SR Tablet | Verapamil (120mg) | Abbott | strip of 15 Tablet pr |
| Calaptin 240 SR Tablet | Verapamil (240mg) | Abbott | strip of 15 Tablet pr |
| Calaptin 40 Tablet | Verapamil (40mg) | Abbott | strip of 30 tablets |
| Calaptin 80 Tablet | Verapamil (80mg) | Abbott | strip of 10 tablets |
| Celovera 2.5mg/ml Injection | Verapamil (2.5mg/ml) | Celon Laboratories Ltd | vial of 2 ml Injection |
| Vasopten 120mg Tablet | Verapamil (120mg) | Torrent Pharmaceuticals Ltd | strip of 10 tablets |
| Vasopten 40mg Tablet | Verapamil (40mg) | Torrent Pharmaceuticals Ltd | strip of 10 tablets |
| Vasopten 80mg Tablet | Verapamil (80mg) | Torrent Pharmaceuticals Ltd | strip of 10 tablets |
| Veramil 40mg Tablet | Verapamil (40mg) | Themis Medicare Ltd | strip of 10 tablets |
| Veramil 80mg Tablet | Verapamil (80mg) | Themis Medicare Ltd | strip of 10 tablets |
| Verap 40mg Tablet | Verapamil (40mg) | Mano Pharma Pvt Ltd | strip of 10 tablets |
| Verap 80mg Tablet | Verapamil (80mg) | Mano Pharma Pvt Ltd | strip of 10 tablets |
| Verpitos 40mg Tablet | Verapamil (40mg) | TOSC International Pvt Ltd | strip of 10 tablets |
| Verpitos 80mg Tablet | Verapamil (80mg) | TOSC International Pvt Ltd | strip of 10 tablets |
| Vpl 2.5mg Injection | Verapamil (2.5mg) | Samarth Life Sciences Pvt Ltd | vial of 2 ml Injection |
| Vpl 5mg Injection | Verapamil (5mg) | Samarth Life Sciences Pvt Ltd | vial of 2 ml Injection |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store at 20 to 25°C (68 to 77°F). Protect from light by retaining in package until ready to use.
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
